Navigation Links
CBI Announces the Agenda for Their West Coast Forum on Clinical Supply Chain Management
Date:9/11/2009

WOBURN, Mass., Sept. 11 /PRNewswire/ -- The Center for Business Intelligence (CBI) is pleased to announce the full agenda for their 2nd West Coast Forum on Clinical Supply Chain Management. The conference takes place in Burlingame, CA, on October 28-29, 2009.

Chaired by Frank Reale (Worldwide Regulatory Coordination and Clinical Supplies, Merck), discussion throughout the conference promises to be both interactive and informative. Particular attention will be paid to actionable takeaways that can have a near-immediate impact on the efficiency of clinical supply chain operations.

The speaking faculty for the event is second to none. Drawing largely from the West Coast, the conference features 13 industry perspectives from organizations including Merck, Schering-Plough, Elan Pharmaceuticals, Cerexa, Santen, Celgene, Facet Biotech, ImClone Systems, MedImmune, Medivation and Talecris. Attendees will network with peers and learn to:

  • Avoid re-labeling costs and risks by using IVR/IWR technology for IMP expiry date management
  • Save money and reduce waste with increased accuracy in supply forecasting
  • Satisfy clinical supply needs regardless of complex sourcing challenges
  • Prevent delays by avoiding or coping with import/export violations
  • Ensure the successful and timely delivery of clinical supplies to sites around the globe
  • Create contingency plans for natural disasters, lost lots, etc.

The conference is the industry's best opportunity to walk away with the latest insights on clinical supply chain management. For more information on the conference or to view the entire agenda, please visit cbinet.com/supplywest
'/>"/>

SOURCE Center for Business Intelligence
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. CryoLife Announces First Clinical Use of BioFoam(R)
2. Martek Announces Settlement of Patent Dispute with Capsugel France
3. Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients
4. Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
5. SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia
6. Misonix Announces New Sales Agency Agreement for Middle East, India and Pakistan
7. Simbionix USA Corporation Announces the Appointment of Mr. Paul Jensen as General Manager for its Growing eLearning and Content Business
8. Biovista Inc. Announces Positive Efficacy Results in a Pre-clinical Trial of its BVA-201 Repositioned Drug for Multiple Sclerosis
9. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
10. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
11. Medivation Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... , EMERYVILLE, Calif., Aug. 6 Onyx Pharmaceuticals, ... to sell an aggregate of four million shares of its common stock ... million aggregate principal amount of its 4.00% convertible senior notes due 2016 ... options to purchase up to an additional 600,000 shares of its common ...
... , ALBANY, Ore., Aug. 6 Synthetech, Inc. (OTC ... of fiscal 2010, which ended June 30, 2009. Revenue for ... of $4.9 million in the first quarter of fiscal 2009. ... operating income of $314,000 for the same period last year. ...
... Md., Aug. 6 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: ... of clinical-stage product candidates for central nervous system disorders, today announced ... on Monday, August 10, 2009, before the market opens. A full ... , , Mihael H. Polymeropoulos, M.D., President and ...
Cached Biology Technology:Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 2Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 3Synthetech Reports First Quarter Fiscal 2010 Results 2Synthetech Reports First Quarter Fiscal 2010 Results 3Synthetech Reports First Quarter Fiscal 2010 Results 4Synthetech Reports First Quarter Fiscal 2010 Results 5Synthetech Reports First Quarter Fiscal 2010 Results 6Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009 2
(Date:4/24/2014)... treatment for a brain infection caused by fungus could now ... to study by University of Liverpool scientists. , Cryptococcus ... fatal but are relatively neglected in medical research. They ... Australasia and South East Asia and mainly affect people with ... a year. , The University research team has tested the ...
(Date:4/24/2014)... the largest river turtle in North America, weighing in ... century. Now researchers from Florida and the University of ... but three. , Examining museum specimens and wild ... ancient reptile. , Once heavily hunted for turtle meat ... Turtle Soup in the 1960s the riverine populations ...
(Date:4/23/2014)... chronic inflammatory disorders among people of lower socioeconomic status ... to the microbes that thrive in rural environments, according ... in the journal Clinical & Experimental Immunology , ... less access to green spaces may be more apt ... system dysfunction. , When our immune systems are working ...
Breaking Biology News(10 mins):Treatment for deadly yeast disease reduced to 3 days 2Two new US turtle species described 2Two new US turtle species described 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3
... Mellon University,s Philip R. LeDuc and his collaborators in ... a protein that could ultimately unlock the mystery of ... role in the mechanics of biological processes in people. ... function of a protein that helps control cell behavior ...
... Reunion in the Indian Ocean and collaborating with researchers at ... sensitive night cameras to capture the first known occurrence of ... only is this the first time this behaviour has been ... who are better known for eating plants but ...
... number of scientists are merging methods and results from different ... team of researchers in a recent issue of Evolution ... new data, however, researchers who want to analyze previous findings ... the authors say. In a commentary piece in the journal ...
Cached Biology News:Carnegie Mellon's Philip LeDuc discovers new protein function 2First known instance of a cricket as an orchid pollinator captured on film by Kew scientist 2Biologists merge methods, results from different disciplines to find new meaning in old data 2Biologists merge methods, results from different disciplines to find new meaning in old data 3
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
With L-glutamine and potassium bicarbonate. Sterile, Insect cell culture tested...
... meet the needs of the ... medium supports fast cell growth ... while maintaining high cell viability ... using the Baculovirus Expression Vector ...
Mol wt: average mol wt12,360.96 Da by calculation...
Biology Products: